Tavist Sinus, available in August, is first Novartis product launch.
This article was originally published in The Tan Sheet
Executive Summary
NOVARTIS TAVIST SINUS TO HIT SHELVES IN AUGUST as the first offspring of the December 1996 marriage of Ciba and Sandoz. Unlike older siblings Tavist-1 and Tavist-D, Tavist Sinus does not contain clemastine fumarate. Each Tavist Sinus tablet contains 500 mg acetaminophen and 30 mg pseudoephedrine HCl, a familiar monograph combination available in a number of currently marketed OTCs, including McNeil's Sine-Aid and Warner Wellcome's Sinutab.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning